# Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis

> **NCT03046251** · PHASE4 · COMPLETED · sponsor: **State University of New York at Buffalo** · enrollment: 30 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT03046251
- **Lead sponsor:** State University of New York at Buffalo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03046251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03046251, "Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03046251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*